Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 6/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2040516 | 0.92 | DAO (0.42) | DAOAURKAAURKBINCENPPDK2 | |
| SCHEMBL31298942 | 0.90 | KDM4E (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL18986576 | 0.90 | KDM4E (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL2527263 | 0.88 | HTR2C (0.55) | HTR2C | |
| SCHEMBL24879971 | 0.87 | DAO (0.42) | DAOAURKAAURKBINCENPPDK2 | |
| Hydrochloric Acid SCHEMBL20292052 | 0.87 | HTR2C (0.56) | HTR2C | |
| SCHEMBL17001657 | 0.85 | HTR1F (0.49) | KDM4E | |
| SCHEMBL8666060 | 0.81 | HTR2C (0.43) | HTR2C | |
| SCHEMBL9998691 | 0.80 | PDK2 (0.34) | DAOAURKAAURKBINCENPPDK2 | |
| SCHEMBL2052042 | 0.79 | KDM4E (0.40) | DAOAURKAAURKBINCENPNAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2025-08-28 | — | — | US | disclosed |
| WO-2025119351-A1 | GPR139 AGONIST | 深圳湾实验室 | 2025-06-12 | — | — | WO | disclosed |
| CN-119998271-A | Pyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20240116922-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4267566-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116940572-A | 2H-indazole derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116867781-A | Imidazo [1,2-a ] pyridine derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2022140425-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140415-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3080121-B1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-9932343-B2 | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-10-20 | — | — | US | disclosed |
| EP-3080121-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086525-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | DAO 3775/4885AURKA 327/4885AURKB 221/4885 |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | DAO 2666/4885AURKA 326/4885AURKB 465/4885 |
| US-20240116922-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK1, IRAK2 | DAO 3684/4885AURKA 284/4885AURKB 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.